Tag: milestone payments

EURneffy (neffy^® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

Data from Orbit and Cosmic studies expected around the end of the year

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
9 JULY 2025 at 13.00 EEST
        

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target